Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Ant308 (TFA) | 99.6% | 3467.10 | 5 MG
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. It significantly enhances the activation and proliferation of T cells, inhibits migration and metastasis, and induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. It can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM).
- Reduces the viability of specific cell lines
- Decreases the proportion of cells in the S phase
- Induces apoptosis in certain cell types
- Inhibits cell migration in multiple cell lines
- Reduces MCAM and N-cadherin expression
- Reduces the number and size of liver metastases in animal models
- Shows a trend toward reducing tumor volume in primary tumor sites in animal models
Medchemexpress LLC F992 TFA | 98.19% | 1028.21 | 1 MG
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue, intended for research use only. This solid, white to off-white compound has a molecular weight of 1028.21 (free base).
- Antidiuretic peptide and vasopressin analogue
- For research use only
- Solid appearance
- White to off-white color
Medchemexpress LLC Alpha-Melanocyte-Stimulating Hormone TFA | 171869-93-5 | 98.5% | 1 MG
α-MSH TFA (α-Melanocyte-Stimulating Hormone TFA) is an endogenous neuropeptide and a melanocortin receptor 4 (MC4R) agonist. It exhibits anti-inflammatory and antipyretic activities and is a post-translational derivative of pro-opiomelanocortin (POMC).
- Endogenous neuropeptide
- MC4R agonist with anti-inflammatory and antipyretic activities
- Post-translational derivative of pro-opiomelanocortin (POMC)
- Modulates CNS inflammation by acting directly on melanocortin receptors in glial cells
- Modulates NFκB activation
- Inhibits translocation of transcription factor κB to the nucleus
Medchemexpress LLC OncoACP3 TFA | 3084147-81-6 | 1323.35 | 5 MG
OncoACP3 TFA | 3084147-81-6 | 1323.35 | 5 MG
Medchemexpress LLC Colivelin TFA | 2803948-60-7 | 99.8% | 2759.12 | 5 MG
Colivelin TFA is a brain-penetrant neuroprotective peptide and a potent activator of STAT3. It suppresses neuronal death in vitro and offers long-term benefits against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. It has potential for treating Alzheimer's disease and ischemic brain injury.
- Suppresses neuronal death and activates neuroprotection through Ca2+/calmodulin-dependent protein kinase IV and STAT3 pathways.
- Reverses caspase3, Bax, and Bcl-2 expressions.
- Increases p-STAT3 protein levels.
- Suppresses spatial working memory impairment and antagonizes hippocampal neuronal loss.
- Improves motor/cognitive function and reduces lesion volume/neurological deficits post-MCAO.
- Protects against cholinotoxin-induced amnesia and ischemic brain injury.
![Medchemexpress LLC L-Prolinamide, N,N-bis(phenylmethyl)glycyl]-4-[4-[[4-[[(phenylmethyl)amino]phosphonomethyl] | 99.9% | 1323.35 | 1 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000386801-logo.png-250.jpg){kind=logo}
Medchemexpress LLC L-Prolinamide, N,N-bis(phenylmethyl)glycyl]-4-[4-[[4-[[(phenylmethyl)amino]phosphonomethyl] | 99.9% | 1323.35 | 1 MG
OncoACP3 TFA from MedChemExpress is a small-molecule ligand of prostatic acid phosphatase (ACP3). This product is applicable to research related to prostate cancer.
- Molecular formula: C62H82F3N12O15P
- Molecular weight: 1323.35
- Appearance: White to off-white solid
- Storage: Powder at -20°C for 3 years; in solvent at -80°C for 6 months, or -20°C for 1 month
- Purity (LCMS): 99.87%
Medchemexpress LLC Mifamurtide (TFA) | 98.0% | 1351.52 | 1 MG
Mifamurtide TFA (MTP-PE TFA) is an analog of the muramyl dipeptide (MDP) that functions as a nonspecific immunomodulator by stimulating the immune response, activating macrophages and monocytes. It is a specific ligand for NOD2 and acts as an insulin sensitizer, with potential applications in rare disease and osteosarcoma research.
- Induces reduction of MG63 cell numbers when co-cultured with macrophages.
- Increases M1 polarization marker iNOS and M2 polarization marker CD206 mRNAs.
- Increases pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines.
- Activates macrophages and monocytes, leading to upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines.
- Shows a trend of diminished spontaneous lung metastasis dissemination in osteosarcoma models.
- Improves glucose tolerance during endotoxemia and in HFD-fed mice.
Medchemexpress LLC Katacalcin TFA | 99.6% | 2550.62 | 25 MG
Katacalcin TFA (PDN 21 TFA) is a potent plasma calcium-lowering peptide from the calcitonin family. It rapidly decreases blood calcium and phosphate by promoting their incorporation into bones. It also deactivates CD14+ peripheral blood mononuclear cell (PBMC) chemotaxis and regulates their migration.
- Potent plasma calcium-lowering peptide
- Belongs to the calcitonin family
- Promotes incorporation of calcium and phosphate into bones
- More potent inhibitor of fMLP-induced chemotaxis
- Deactivates CD14+ peripheral blood mononuclear cell (PBMC) chemotaxis
- Regulates human CD14+ PBMC migration
Medchemexpress LLC GRGDSP TFA | 98.0% | 701.61 | 25 MG
GRGDSP (TFA) is an integrin inhibitor. This synthetic linear RGD peptide can inhibit the adherence of tumor cells to endothelial cells of blood vessels, thereby limiting metastasis. It is also utilized to modify the surface of cardiovascular implants, such as vascular grafts, to promote endothelialization, and is widely employed in integrin research as a soluble integrin-blocking RGD-based peptide.
- Inhibits adherence of tumor cells to endothelial cells of blood vessels
- Limits metastasis
- Promotes endothelialization for cardiovascular implants
- Used in integrin research
- Functions as a soluble integrin-blocking RGD-based peptide
Medchemexpress LLC AT-1002 TFA | 835872-35-0 | 99.5% | 821.91 | 1 ML
AT-1002 TFA, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer. It belongs to an emerging novel class of compounds that reversibly increase paracellular transport of molecules across the epithelial barrier.
- Can undergo Cys-Cys dimerization.
- Treatment for up to 3 hours did not affect Caco-2 cell viability at any concentration.
- Reduced cell viability after 24 hours at concentrations of 2.5 mg/mL and higher.
- Cells remained viable after 24 hours if washed after 3 hours exposure, indicating it does not irreversibly damage cells.
Medchemexpress LLC VU0364572 (TFA) | 1240514-89-9 | 99.3% | 487.51 | 25 MG
VU0364572 TFA is an orally active and selective allosteric agonist of the M1 muscarinic receptor with an EC50 of 0.11 μM. It demonstrates neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer's Disease and is CNS penetrant.
- Orally active and selective allosteric agonist of the M1 muscarinic receptor.
- Neuroprotective potential for preventing memory impairments.
- Reduces neuropathology in Alzheimer's Disease.
- CNS penetrant.
Medchemexpress LLC 7-TFA-ap-7-Deaza-dA | 178420-75-2 | 98.8% | 399.32 | 1 ML
7-TFA-ap-7-Deaza-dA is a modified nucleoside that can be used in the synthesis of deoxyribonucleic acid or nucleic acid. It functions as a click chemistry reagent, containing an alkyne group that undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules.
- Modified nucleoside.
- Can be used in the synthesis of deoxyribonucleic acid or nucleic acid.
- Functions as a click chemistry reagent.
- Contains an alkyne group for reactions.
- Undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide groups.
Medchemexpress LLC 2-Furancarboxamide, 5-nitro-N-[4-[7-(1,2,3,6-tetrahydro-4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl] | C25H20F3N5O6 | 5 MG
W1131 TFA is a potent STAT3 inhibitor that induces ferroptosis. It inhibits cancer progression in subcutaneous xenograft, organoid, and PDX models of gastric cancer. W1131 effectively alleviates cancer cell chemoresistance to 5-FU, and regulates the cell cycle, DNA damage response, and oxidative phosphorylation, including the IL6-JAK-STAT3 pathway and the ferroptosis pathway.
- Potent STAT3 inhibitor
- Induces ferroptosis
- Inhibits cancer progression in gastric cancer models
- Alleviates cancer cell chemoresistance to 5-FU
- Regulates cell cycle and DNA damage response
- Regulates oxidative phosphorylation
- Regulates IL6-JAK-STAT3 pathway
- Regulates ferroptosis pathway